Boehringer Ingelheim to Acquires Labor Dr. Merk & Kollegen for Boosting its Next Generation Cancer Immunology Program
Shots: The acquisition will enable Boehringer Ingelheim to expand and accelerate its comprehensive program for the development of ATMP-based immuno-oncology therapies including the VSV with modified GP platform and cancer vaccines platforms The addition of Labor Dr. Merk & Kollegen’s site will enable Boehringer Ingelheim to further strengthen its oncolytic virus and cancer vaccine development […]